News
Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6
- Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections
JERUSALEM, Israel, July 13, 2026 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the launch of the PEPTAMR consortium, bringing together leading European clinical, scientific, and academic partners to accelerate the late-stage clinical development of OMN6, its lead antimicrobial peptide targeting resistant hospital-acquired infections (HAIs), including carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO critical-priority pathogen associated with mortality rates of up to 60% and severely limited treatment options. Read more…
TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory Pathway in Kidney Transplantation
- Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients
- Strengthening MIC-Lxâs regulatory and commercial positioning in Europe
TolerogenixX, a German clinical-stage biopharmaceutical company developing personalized cell therapies inducing antigen-specific immune tolerance, today announced that the European Commission has granted MIC-Lx, the Company’s lead product candidate, Orphan Drug Designation (ODD) for living-donor kidney transplantation following a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Read more…
TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New Immune Tolerance Approach in Kidney Transplantation
- All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers
- Randomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a first-in-class immune tolerance-inducing cell therapy, in living-donor kidney transplantation
- Designed to address one of transplantation’s key issues: lifelong systemic immunosuppression
- Key milestone in the clinical development of MIC-Lx and TolerogenixX’s proprietary MIC technology platform
TolerogenixX, a clinical-stage biopharmaceutical company founded in 2016 developing personalized cell therapies to induce antigen-specific immune tolerance, today announced that the last patient has undergone kidney transplantation in TOL-2, the Company’s randomized, controlled Phase IIb clinical trial evaluating MIC-Lx in living-donor kidney transplantation (ClinicalTrials.gov identifier: NCT05365672 and EudraCT No.: 2021-000561-33).
Omnix Medical Announces First Patients Dosed in Phase II Trial of Antimicrobial Lead Compound OMN6
— Novel mechanism of action based on the direct physical elimination of pathogenic bacteria
— First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for severe multidrug-resistant infections, announced today that the first patients in a Phase II trial (NCT06087536)[1] have been dosed with its lead compound OMN6, a first-in-class antimicrobial targeting severe multidrug-resistant Acinetobacter baumannii infections associated with high mortality and limited treatment options. Read more…